FDA
-
-
-
-
-
-
-
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
-
-
-
-
-
-
-
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
-
-
-
-
-
-
-
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
-
-
-
-
-
-
-
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
-
-
-
-
-
-
-
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
-
-
-
-
-
-
-
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
-
-
-
-
-
-
-
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previo
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

